These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16358829)

  • 1. [Seroprevalence of measles antibody and its attributable factors in elementary students of routine 2-dose schedule era with vaccination record].
    Bae GR; Lim HS; Goh UY; Yang BG; Kim YT; Lee JK
    J Prev Med Public Health; 2005 Nov; 38(4):431-6. PubMed ID: 16358829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children.
    Rafiei Tabatabaei S; Esteghamati AR; Shiva F; Fallah F; Radmanesh R; Abdinia B; Shamshiri AR; Khairkhah M; Shekari Ebrahimabad H; Karimi A
    Arch Iran Med; 2013 Jan; 16(1):38-41. PubMed ID: 23273235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
    Gohil DJ; Kothari ST; Chaudhari AB; Gunale BK; Kulkarni PS; Deshmukh RA; Chowdhary AS
    Viral Immunol; 2016 Apr; 29(3):159-63. PubMed ID: 26910764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
    Saffar MJ; Fathpour GR; Parsaei MR; Ajami A; Khalilian AR; Shojaei J; Saffar H
    J Trop Pediatr; 2011 Oct; 57(5):347-51. PubMed ID: 21078605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
    Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
    J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.
    Leuridan E; Maertens K; Wautier M; Hutse V; Theeten H
    Eur J Pediatr; 2015 Jul; 174(7):925-32. PubMed ID: 25579232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outbreak of measles in primary school students with high first dose MMR vaccination coverage.
    Ong G; Rasidah N; Wan S; Cutter J
    Singapore Med J; 2007 Jul; 48(7):656-61. PubMed ID: 17609829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal.
    Gonçalves G; Frade J; Nunes C; Mesquita JR; Nascimento MS
    Vaccine; 2015 Sep; 33(39):5057-63. PubMed ID: 26319061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained measles elimination in Australia and priorities for long term maintenance.
    Gidding HF; Wood J; MacIntyre CR; Kelly H; Lambert SB; Gilbert GL; McIntyre PB
    Vaccine; 2007 May; 25(18):3574-80. PubMed ID: 17300858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
    J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
    Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
    Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.
    Yekta Z; Pourali R; Taravati MR; Shahabi S; Salary S; Khalily F; Farzin A
    East Mediterr Health J; 2009; 15(3):516-25. PubMed ID: 19731767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mumps antibody in the Thai population 17 years after the universal measles mumps rubella vaccination program.
    Ngaovithunvong V; Wanlapakorn N; Tesapirat L; Suratannon N; Poovorawan Y
    J Infect Dev Ctries; 2016 Aug; 10(7):735-40. PubMed ID: 27482805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R; Rahman MM; Hassan Z; Hassan MS
    Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.